NLS Pharmaceutics AG (NLSP) — Strategic Asset Allocation Index
NLS Pharmaceutics AG (NLSP) has a Strategic Asset Allocation Index of 5.4% as of December 2021. Strategic assets (PP&E of $29.51K plus long-term investments of $-) total $29.51K, measured against net assets of $542.39K. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See NLS Pharmaceutics AG (NLSP) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
NLS Pharmaceutics AG Strategic Asset Allocation Index (2021–2021)
This chart shows how NLS Pharmaceutics AG's Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of December 2021, the index stands at 5.4%, representing strategic assets of $29.51K against net assets of $542.39K USD. For live market cap and overall valuation, see NLS Pharmaceutics AG market capitalisation.
Annual Strategic Asset Allocation Index for NLS Pharmaceutics AG (2021–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for NLS Pharmaceutics AG from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See shareholders equity of NLS Pharmaceutics AG for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 5.4% | $29.51K | $29.51K | $- | $542.39K | — |